EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Systemic therapies in hepatocellular carcinoma: A revolution?

Marta Fortuny iD, Marco Sanduzzi-Zamparelli iD, Maria Reig iD

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12510 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Marta Fortuny und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Clinic Liver Cancer (BCLC) Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Científica De La Asociación Española Contra El Cáncer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution in systemic therapies in hepatocellular carcinoma (HCC) signifies a strategy of high‐cost, high‐gain innovation that originated with sorafenib, despite its limited impact on tumor response. This strategic approach paved the way for the emergence of a second wave of the short‐lived competitive advantage, exemplified by the incorporation of atezolizumab plus bevacizumab and tremelimumab plus durvalumab. In the context of safety concerns within the liver cancer domain, the IMBRAVE150 and HIMALAYA trials boldly incorporated bevacizumab and tremelimumab, respectively, demonstrating the continuation of the high‐risk, high‐reward innovation paradigm. This review delves into the strengths, weaknesses, opportunities, and threats analysis of systemic therapies in the field of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansBevacizumabSorafenib

Stichwörter der Autor:innen

HCCadvanced HCCatezolizumabbevacizumabdurvalumabhepatocellular carcinomaimmunotherapysystemic therapytargeted therapytremelimumab

Substanzen

BevacizumabSorafenib

Autor:innen und Institutionen

  • Barcelona Clinic Liver Cancer (BCLC) Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Liver Oncology Unit, Liver Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
  • Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Barcelona University, Barcelona, Spain.

ORCID-Profile: Marta Fortuny, Marco Sanduzzi-Zamparelli, Maria Reig

Förderung

  • Instituto de Salud Carlos III
  • Fundación Científica De La Asociación Española Contra El Cáncer

Zitieren

APA

Fortuny, M., Sanduzzi-Zamparelli, M., & Reig, M. (2024). Systemic therapies in hepatocellular carcinoma: A revolution?. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12510

Vancouver

Fortuny M, Sanduzzi-Zamparelli M, Reig M. Systemic therapies in hepatocellular carcinoma: A revolution?. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12510

BibTeX
@article{Fortuny2024,
  author = {Fortuny, Marta and Sanduzzi-Zamparelli, Marco and Reig, Maria},
  title = {Systemic therapies in hepatocellular carcinoma: A revolution?},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12510}
}
Kostenlos starten →